Seres Therapeutics, Inc. (MCRB)

Market Cap	139.81M
Revenue (ttm)	n/a
Net Income (ttm)	85.97M
Shares Out	8.75M
EPS (ttm)	10.22
PE Ratio	1.56
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	99,634
Open	15.42
Previous Close	15.44
Day's Range	15.14 - 15.99
52-Week Range	6.53 - 26.40
Beta	2.89
Analysts	Hold
Price Target	73.67 (+361.3%)
Earnings Date	Aug 6, 2025

About MCRB

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic comp...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2015
• Employees: 103
• Stock Exchange: NASDAQ
• Ticker Symbol: MCRB
• Website: https://www.serestherapeutics.com

Analyst Forecast

According to 4 analysts, the average rating for MCRB stock is "Hold." The 12-month stock price target is $73.67, which is an increase of 361.30% from the latest price.

Price Target

$73.67

(361.30% upside)

Analyst Consensus: Hold